Product Images Alendronate Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Alendronate Sodium NDC 68071-1514 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
PDP - 68071 1514 4
This appears to be a medical label for a product called Alendronate Sodium 70mg, which comes in a package of 4 tablets. The label includes a warning to keep the product out of reach of children and provides contact information to call a doctor in case of side effects. The lot number and expiration date are also indicated. There are some characters that cannot be identified, possibly indicating some errors.*
Figure 1 - alendronate fig1
The text refers to a graph showing the cumulative incidence of hip fractures in a three-year study of FIT, specifically in patients with radiographic vertebral fractures at baseline. The graph includes data for the Placsbo and Alendronate Sodium treatments, with the x-axis indicating the time in months and the y-axis indicating the percentage of patients experiencing hip fractures. No additional information is available from the provided text.*
Figure 2 - alendronate fig2
This is a table with the results from a study on osteoporosis treatment for postmenopausal women. The table includes the percentage increase in Bone Mineral Density (BMD) for three different areas of the body: lumbar spine, femoral neck, and trochanter. The study compares the results of alendronate 10 mg/day at three years to a placebo. The mean increase in BMD and standard error (SE) are also provided.*
Figure 3 - alendronate fig3
This is a graph showing the mean percent change from baseline in lumbar spine bone mineral density (BMD) in postmenopausal women treated with Alendronate 10 mg/day versus Placebo over a period of 36 months. The multinational study included Alendronate and placebo as treatments. The X-axis represents time in months and the Y-axis represents the percent change from the baseline BMD. The graph suggests that Alendronate treatment resulted in a significant increase in lumbar spine BMD compared to placebo over the 36-month period.*
Figure 4 - alendronate fig4
Figure 5 - alendronate fig5
Figure 6 - alendronate fig6
The text provides a chart showing the effect of Alendronate 40mg/day on serum alkaline phosphatase in Paget's Disease of Bone, compared to placebo or Etidronate 400mg/day. The chart includes the mean percentage change from baseline at 0, 3, and 6 months. The study includes a multinational study and a U.S. study with sample sizes of 27 and 41, respectively.*
Chemical Structure - alendronate str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.